CAS 114899-77-3
:Trabectedin
Description:
Trabectedin, also known by its developmental code ET-743, is a synthetic alkaloid derived from the marine tunicate Ecteinascidia turbinata. It is primarily used as an antineoplastic agent in cancer therapy, particularly for soft tissue sarcomas and ovarian cancer. Trabectedin functions by binding to DNA and disrupting the transcription process, leading to cell cycle arrest and apoptosis in cancer cells. Its mechanism of action involves the formation of DNA adducts, which interfere with the normal function of the cell's machinery. The compound exhibits a unique structure characterized by a complex polycyclic core and a functionalized side chain, contributing to its biological activity. Trabectedin is administered intravenously and has a specific pharmacokinetic profile, including a relatively short half-life and extensive protein binding. Side effects may include myelosuppression, liver enzyme elevation, and gastrointestinal disturbances. Due to its unique origin and mechanism, Trabectedin represents a significant advancement in targeted cancer therapies, highlighting the potential of marine-derived compounds in medicinal chemistry.
Formula:C39H43N3O11S
InChI:InChI=1/C40H45N3O11S/c1-17-11-21-12-23-38(47)43-24-15-51-39(48)40(22-14-26(49-5)25(45)13-20(22)7-9-41-40)8-10-55-37(31(43)30(42(23)4)27(21)32(46)33(17)50-6)29-28(24)36-35(52-16-53-36)18(2)34(29)54-19(3)44/h11,13-14,23-24,30-31,37-38,41,45-47H,7-10,12,15-16H2,1-6H3/t23-,24-,30+,31+,37+,38-,40+/m0/s1
InChI key:InChIKey=PKVRCIRHQMSYJX-AIFWHQITSA-N
SMILES:O[C@@H]1N2[C@@]([C@]3(C=4C([C@@]2(COC(=O)[C@@]5(CS3)C=6C(=CC(O)=C(OC)C6)CCN5)[H])=C7C(=C(C)C4OC(C)=O)OCO7)[H])([C@]8(C=9C(C[C@@]1(N8C)[H])=CC(C)=C(OC)C9O)[H])[H]
Synonyms:- (1'R,6R,6aR,7R,13S,14S,16R)-6',8,14-Trihydroxy-7',9-dimethoxy-4,10,23-trimethyl-19-oxo-3',4',6,7,12,13,14,16-octahydrospiro(6,16-(epithiopropanooxymethano)-7,13-imino-6aH-1,3-dioxolo(7,8)isoquino(3,2-b)(3)benzazocine-20,1'(2'H)-isoquinolin)-5-yl acetate
- (1′R,6R,6aR,7R,13S,14S,16R)-5-(Acetyloxy)-3′,4′,6,6a,7,13,14,16-octahydro-6′,8,14-trihydroxy-7′,9-dimethoxy-4,10,23-trimethylspiro[6,16-(epithiopropanoxymethano)-7,13-imino-12H-1,3-dioxolo[7,8]isoquino[3,2-b][3]benzazocine-20,1′(2′H)-isoquinolin]-19-one
- 1,3-Benzodioxole-5-propanoic acid,7-methyl-6-(phenylmethoxy)-α-[[(phenylmethoxy)carbonyl]amino]-,2,2-dimethoxyethyl ester
- Ccris 8133
- Ect 743
- Ecteinascidin
- Ecteinascidine 743
- Et-743
- Nsc 648766
- Spiro(6,16-(epithiopropanoxymethano)-7,13-imino-12H-1,3-dioxolo(7,8)isoquino(3,2,-b)(3)benzazocine-20,1'(2'H)-isoquinolin)-19-one, 3',4',6,6a,7,13,14,16-octahydro-5-(acetyloxy)-6',8,14-trihydroxy-7',9-dimethoxy-4,10,23-trimethyl-, (6R-(6-alpha,6a-beta,7-beta,13-beta,14-beta,16-alpha,20R*))-
- Spiro(6,16-(epithiopropanoxymethano)-7,13-imino-12H-1,3-dioxolo(7,8)isoquino(3,2,-b)(3)benzazocine-20,1'(2'H)-isoquinolin)-19-one, 5-(acetyloxy)-3',4',6,6a,7,13,14,16-octahydro-6',8,14-trihydroxy-7',9-dimethoxy-4,10,23-trimethyl-, (1'R,6R,6aR,7R,13S,14S,16R)-
- Spiro[6,16-(epithiopropanoxymethano)-7,13-imino-12H-1,3-dioxolo[7,8]isoquino[3,2-b][3]benzazocine-20,1′(2′H)-isoquinolin]-19-one, 5-(acetyloxy)-3′,4′,6,6a,7,13,14,16-octahydro-6′,8,14-trihydroxy-7′,9-dimethoxy-4,10,23-trimethyl-, (1′R,6R,6aR,7R,13S,14S,16R)-
- Spiro[6,16-(epithiopropanoxymethano)-7,13-imino-12H-1,3-dioxolo[7,8]isoquino[3,2-b][3]benzazocine-20,1′(2′H)-isoquinolin]-19-one, 5-(acetyloxy)-3′,4′,6,6a,7,13,14,16-octahydro-6′,8,14-trihydroxy-7′,9-dimethoxy-4,10,23-trimethyl-, [6R-(6α,6aβ,7β,13β,14β,16α,20R*)]-
- Trabectedin
- Unii-Id0Yzq2Tcp
- Yondelis
- ecteinascidin 743
- ecteinascidin 743,Trabectedin,ET 743
- Trabectedin Q: What is the storage condition of
- PKVRCIRHQMSYJX-ZKZLGIKISA-N
- (1'R,6R,6aR,7R,13S,14S,16R)-
- Trabectedin Q: What is the CAS Number of
- ASMF Filed
- NSC-684766
- ECTEINASCIDIN 743; ET-743; ECTEINASCIDIN
- Trabectedin (Ecteinascidin 743)
- Trabectedin Q: What are the applications of
- Trabectedin (Yondelis)
- Yondelis R ,Trabectedin
- TrabectedinQ: What is
- Trabectedin(Ecteinascidin 743,NSC-684766,ET-743)
- Trabectedin, >95%
- Trabectedin(Ecteinascidin 743,NSC-684766,ET-743, Yondelis)
- cteinascidin
- See more synonyms
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
Found 6 products.
Ref: IN-DA008TKA
1gTo inquire1mg180.00€5mg589.00€10mg626.00€25mgTo inquire50mgTo inquire250mgTo inquireTrabectedin
CAS:<p>Trabectedin (Ecteinascidin 743) has potent antitumor activity and the potential for soft tissue sarcoma and ovarian cancer research.</p>Formula:C39H43N3O11SPurity:≥98%Color and Shape:SolidMolecular weight:761.84Trabectedin
CAS:Controlled Product<p>Applications A tetrahydroisoquinoline alkaloid with antitumor activity isolated from the Caribbean tunicate, Ecteinascidin turbinata. It is the first marine anticancer agent approved in the European Union for patients with soft tissue sarcoma (STS). Antineoplastic.<br>References Sakai, R., et al.: Proc. Natl. Acad. Sci., 89, 11456 (1992), Aune, G., et al.: Anticancer Drugs, 13, 545 (2002), Herrero, A., et al.: Cancer Res., 66, 8155 (2006), Sugasawa, K., et al.: Carcinogenesis, 29, 455 (2008),<br></p>Formula:C39H43N3O11SColor and Shape:NeatMolecular weight:761.84Trabectedin
CAS:<p>Trabectedin is a model system for investigating the role of protein genes in cancer. It is used for high throughput screening of potential biomarkers, such as blood sampling and mouse tumor models. Trabectedin has been shown to be a potent inhibitor of the p-gp substrate and has been used in vivo to treat cancers, including solid tumors and experimental models. This drug was also found to inhibit the antitumor response in normal human cells. Trabectedin is a taxane derivative that binds to the surface of cells with high affinity and prevents phosphorylation of proteins on the cell surface, which leads to inhibition of cell proliferation.</p>Formula:C39H43N3O11SPurity:Min. 95%Color and Shape:White/Off-White SolidMolecular weight:761.84 g/mol





